AustralieFrV1, Main, Exploration, bibRecord, 008E73

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells

Identifieur interne : 008E73 ( Main/Exploration ); précédent : 008E72; suivant : 008E74

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells

Auteurs : K. A. Benhadji [France] ; M. Serova [France] ; A. Ghoul [France] ; E. Cvitkovic [France] ; C. Le Tourneau [France] ; S. M. Ogbourne [Australie] ; F. Lokiec [France] ; F. Calvo [France] ; P. Hammel [France] ; S. Faivre [France] ; E. Raymond [France]

Source :

British journal of cancer [ 0007-0920 ] ; 2008.

RBID : Pascal:09-0049469

Descripteurs français

Pascal (Inist)
- Cancer du côlon, Anticancéreux, Activité biologique, Protein kinase C, Association médicamenteuse, Homme, Cellule tumorale, Protein kinase Cδ, Mitogen-activated protein kinase, Résistance traitement, Cancérologie.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Antineoplastic agent, Biological activity, Cancerology, Colon cancer, Drug combination, Human, Mitogen-activated protein kinase, Protein kinase C, Protein kinase Cδ, Treatment resistance, Tumor cell.

Abstract

PEP005 is a novel ingenol angelate that modulates protein kinases C (PKC) functions by activating PKCδ and inhibiting PKCa. This study assessed the antiproliferative effects of PEP005 alone and in combination with several other anticancer agents in a panel of 10 human cancer cell lines characterised for expression of several PKC isoforms. PEP005 displayed antiproliferative effects at clinically relevant concentrations with a unique cytotoxicity profile that differs from that of most other investigated cytotoxic agents, including staurosporine. In a subset of colon cancer cells, the IC₅₀ of PEP005 ranged from 0.01 - 140 μM. The antiproliferative effects of PEP005 were shown to be concentration- and time-dependent. In Colo205 cells, apoptosis induction was observed at concentrations ranging from 0.03 to 3 μM. Exposure to PEP005 also induced accumulation of cells in the G I phase of the cell cycle. In addition, PEP005 increased the phosphorylation of PKCδ and p38. In Colo205 cells, combinations of PEP005 with several cytotoxic agents including oxaliplatin, SN38, 5FU, gemcitabine, doxorubicin, vinorelbine, and docetaxel yielded sequence-dependent antiproliferative effects. Cell cycle blockage induced by PEP005 in late Gl lasted for up to 24 h and therefore a 24h lag-time between PEP005 and subsequent exposure to cytotoxics was required to optimise PEP005 combinations with several anticancer agents. These data support further evaluation of PEP005 as an anticancer agent and may help to optimise clinical trials with PEP005-based combinations in patients with solid tumours.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600681

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells</title>
<author><name sortKey="Benhadji, K A" sort="Benhadji, K A" uniqKey="Benhadji K" first="K. A." last="Benhadji">K. A. Benhadji</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U728, RayLab, Department of Medical Oncology, Beau/on University Hospital, APHP, Paris 7, 100 boulevard Général Leclerc</s1>
<s2>Clichy 92110</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>92110</wicri:noRegion>
<wicri:noRegion>100 boulevard Général Leclerc</wicri:noRegion>
<wicri:noRegion>Clichy 92110</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of clinical Pharmacology, Rend Huguenin Cancer Center, 35 rue Dailly</s1>
<s2>Saint-Cloud 92210</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>92210</wicri:noRegion>
<wicri:noRegion>35 rue Dailly</wicri:noRegion>
<wicri:noRegion>Saint-Cloud 92210</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Serova, M" sort="Serova, M" uniqKey="Serova M" first="M." last="Serova">M. Serova</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U728, RayLab, Department of Medical Oncology, Beau/on University Hospital, APHP, Paris 7, 100 boulevard Général Leclerc</s1>
<s2>Clichy 92110</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>92110</wicri:noRegion>
<wicri:noRegion>100 boulevard Général Leclerc</wicri:noRegion>
<wicri:noRegion>Clichy 92110</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ghoul, A" sort="Ghoul, A" uniqKey="Ghoul A" first="A." last="Ghoul">A. Ghoul</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U728, RayLab, Department of Medical Oncology, Beau/on University Hospital, APHP, Paris 7, 100 boulevard Général Leclerc</s1>
<s2>Clichy 92110</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>92110</wicri:noRegion>
<wicri:noRegion>100 boulevard Général Leclerc</wicri:noRegion>
<wicri:noRegion>Clichy 92110</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of clinical Pharmacology, Rend Huguenin Cancer Center, 35 rue Dailly</s1>
<s2>Saint-Cloud 92210</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>92210</wicri:noRegion>
<wicri:noRegion>35 rue Dailly</wicri:noRegion>
<wicri:noRegion>Saint-Cloud 92210</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cvitkovic, E" sort="Cvitkovic, E" uniqKey="Cvitkovic E" first="E." last="Cvitkovic">E. Cvitkovic</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U728, RayLab, Department of Medical Oncology, Beau/on University Hospital, APHP, Paris 7, 100 boulevard Général Leclerc</s1>
<s2>Clichy 92110</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>92110</wicri:noRegion>
<wicri:noRegion>100 boulevard Général Leclerc</wicri:noRegion>
<wicri:noRegion>Clichy 92110</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Le Tourneau, C" sort="Le Tourneau, C" uniqKey="Le Tourneau C" first="C." last="Le Tourneau">C. Le Tourneau</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U728, RayLab, Department of Medical Oncology, Beau/on University Hospital, APHP, Paris 7, 100 boulevard Général Leclerc</s1>
<s2>Clichy 92110</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>92110</wicri:noRegion>
<wicri:noRegion>100 boulevard Général Leclerc</wicri:noRegion>
<wicri:noRegion>Clichy 92110</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ogbourne, S M" sort="Ogbourne, S M" uniqKey="Ogbourne S" first="S. M." last="Ogbourne">S. M. Ogbourne</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Peplin Ltd, I Breakfast Creek Road, Newstead Brisbane</s1>
<s2>Queensland 4006</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Queensland 4006</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lokiec, F" sort="Lokiec, F" uniqKey="Lokiec F" first="F." last="Lokiec">F. Lokiec</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of clinical Pharmacology, Rend Huguenin Cancer Center, 35 rue Dailly</s1>
<s2>Saint-Cloud 92210</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>92210</wicri:noRegion>
<wicri:noRegion>35 rue Dailly</wicri:noRegion>
<wicri:noRegion>Saint-Cloud 92210</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calvo, F" sort="Calvo, F" uniqKey="Calvo F" first="F." last="Calvo">F. Calvo</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>INSERM U716 IGM-Saint-Louis Hospital, APHP, Pans 7, 27 rue Juliette Dodu</s1>
<s2>Paris 75010</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>75010</wicri:noRegion>
<placeName><settlement type="city">Paris</settlement>
<region type="région" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hammel, P" sort="Hammel, P" uniqKey="Hammel P" first="P." last="Hammel">P. Hammel</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U728, RayLab, Department of Medical Oncology, Beau/on University Hospital, APHP, Paris 7, 100 boulevard Général Leclerc</s1>
<s2>Clichy 92110</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>92110</wicri:noRegion>
<wicri:noRegion>100 boulevard Général Leclerc</wicri:noRegion>
<wicri:noRegion>Clichy 92110</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Faivre, S" sort="Faivre, S" uniqKey="Faivre S" first="S." last="Faivre">S. Faivre</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U728, RayLab, Department of Medical Oncology, Beau/on University Hospital, APHP, Paris 7, 100 boulevard Général Leclerc</s1>
<s2>Clichy 92110</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>92110</wicri:noRegion>
<wicri:noRegion>100 boulevard Général Leclerc</wicri:noRegion>
<wicri:noRegion>Clichy 92110</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Raymond, E" sort="Raymond, E" uniqKey="Raymond E" first="E." last="Raymond">E. Raymond</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U728, RayLab, Department of Medical Oncology, Beau/on University Hospital, APHP, Paris 7, 100 boulevard Général Leclerc</s1>
<s2>Clichy 92110</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>92110</wicri:noRegion>
<wicri:noRegion>100 boulevard Général Leclerc</wicri:noRegion>
<wicri:noRegion>Clichy 92110</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0049469</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 09-0049469 INIST</idno>
<idno type="RBID">Pascal:09-0049469</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003057</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002F60</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003405</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">003405</idno>
<idno type="wicri:doubleKey">0007-0920:2008:Benhadji K:antiproliferative:activity:of</idno>
<idno type="wicri:Area/Main/Merge">009819</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600681</idno>
<idno type="RBID">PMC:2600681</idno>
<idno type="wicri:Area/Pmc/Corpus">000141</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000141</idno>
<idno type="wicri:Area/Pmc/Curation">000141</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000141</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002A45</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002A45</idno>
<idno type="wicri:Area/Ncbi/Merge">000486</idno>
<idno type="wicri:Area/Ncbi/Curation">000486</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000486</idno>
<idno type="wicri:doubleKey">0007-0920:2008:Benhadji K:antiproliferative:activity:of</idno>
<idno type="wicri:Area/Main/Merge">008E84</idno>
<idno type="wicri:Area/Main/Curation">008E73</idno>
<idno type="wicri:Area/Main/Exploration">008E73</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells</title>
<author><name sortKey="Benhadji, K A" sort="Benhadji, K A" uniqKey="Benhadji K" first="K. A." last="Benhadji">K. A. Benhadji</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM U728, RayLab, Department of Medical Oncology, Beau/on University Hospital, APHP, Paris 7, 100 boulevard Général Leclerc</s1>
<s2>Clichy 92110</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of clinical Pharmacology, Rend Huguenin Cancer Center, 35 rue Dailly</s1>
<s2>Saint-Cloud 92210</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Serova, M" sort="Serova, M" uniqKey="Serova M" first="M." last="Serova">M. Serova</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM U728, RayLab, Department of Medical Oncology, Beau/on University Hospital, APHP, Paris 7, 100 boulevard Général Leclerc</s1>
<s2>Clichy 92110</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ghoul, A" sort="Ghoul, A" uniqKey="Ghoul A" first="A." last="Ghoul">A. Ghoul</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM U728, RayLab, Department of Medical Oncology, Beau/on University Hospital, APHP, Paris 7, 100 boulevard Général Leclerc</s1>
<s2>Clichy 92110</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of clinical Pharmacology, Rend Huguenin Cancer Center, 35 rue Dailly</s1>
<s2>Saint-Cloud 92210</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cvitkovic, E" sort="Cvitkovic, E" uniqKey="Cvitkovic E" first="E." last="Cvitkovic">E. Cvitkovic</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM U728, RayLab, Department of Medical Oncology, Beau/on University Hospital, APHP, Paris 7, 100 boulevard Général Leclerc</s1>
<s2>Clichy 92110</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Le Tourneau, C" sort="Le Tourneau, C" uniqKey="Le Tourneau C" first="C." last="Le Tourneau">C. Le Tourneau</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM U728, RayLab, Department of Medical Oncology, Beau/on University Hospital, APHP, Paris 7, 100 boulevard Général Leclerc</s1>
<s2>Clichy 92110</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ogbourne, S M" sort="Ogbourne, S M" uniqKey="Ogbourne S" first="S. M." last="Ogbourne">S. M. Ogbourne</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Peplin Ltd, I Breakfast Creek Road, Newstead Brisbane</s1>
<s2>Queensland 4006</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Queensland 4006</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lokiec, F" sort="Lokiec, F" uniqKey="Lokiec F" first="F." last="Lokiec">F. Lokiec</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of clinical Pharmacology, Rend Huguenin Cancer Center, 35 rue Dailly</s1>
<s2>Saint-Cloud 92210</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>92210</wicri:noRegion>
<wicri:noRegion>35 rue Dailly</wicri:noRegion>
<wicri:noRegion>Saint-Cloud 92210</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calvo, F" sort="Calvo, F" uniqKey="Calvo F" first="F." last="Calvo">F. Calvo</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>INSERM U716 IGM-Saint-Louis Hospital, APHP, Pans 7, 27 rue Juliette Dodu</s1>
<s2>Paris 75010</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>75010</wicri:noRegion>
<placeName><settlement type="city">Paris</settlement>
<region type="région" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hammel, P" sort="Hammel, P" uniqKey="Hammel P" first="P." last="Hammel">P. Hammel</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U728, RayLab, Department of Medical Oncology, Beau/on University Hospital, APHP, Paris 7, 100 boulevard Général Leclerc</s1>
<s2>Clichy 92110</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>92110</wicri:noRegion>
<wicri:noRegion>100 boulevard Général Leclerc</wicri:noRegion>
<wicri:noRegion>Clichy 92110</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Faivre, S" sort="Faivre, S" uniqKey="Faivre S" first="S." last="Faivre">S. Faivre</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U728, RayLab, Department of Medical Oncology, Beau/on University Hospital, APHP, Paris 7, 100 boulevard Général Leclerc</s1>
<s2>Clichy 92110</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>92110</wicri:noRegion>
<wicri:noRegion>100 boulevard Général Leclerc</wicri:noRegion>
<wicri:noRegion>Clichy 92110</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Raymond, E" sort="Raymond, E" uniqKey="Raymond E" first="E." last="Raymond">E. Raymond</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U728, RayLab, Department of Medical Oncology, Beau/on University Hospital, APHP, Paris 7, 100 boulevard Général Leclerc</s1>
<s2>Clichy 92110</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>92110</wicri:noRegion>
<wicri:noRegion>100 boulevard Général Leclerc</wicri:noRegion>
<wicri:noRegion>Clichy 92110</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">British journal of cancer</title>
<title level="j" type="abbreviated">Br. J. cancer</title>
<idno type="ISSN">0007-0920</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">British journal of cancer</title>
<title level="j" type="abbreviated">Br. J. cancer</title>
<idno type="ISSN">0007-0920</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term>
<term>Biological activity</term>
<term>Cancerology</term>
<term>Colon cancer</term>
<term>Drug combination</term>
<term>Human</term>
<term>Mitogen-activated protein kinase</term>
<term>Protein kinase C</term>
<term>Protein kinase Cδ</term>
<term>Treatment resistance</term>
<term>Tumor cell</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Cancer du côlon</term>
<term>Anticancéreux</term>
<term>Activité biologique</term>
<term>Protein kinase C</term>
<term>Association médicamenteuse</term>
<term>Homme</term>
<term>Cellule tumorale</term>
<term>Protein kinase Cδ</term>
<term>Mitogen-activated protein kinase</term>
<term>Résistance traitement</term>
<term>Cancérologie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">PEP005 is a novel ingenol angelate that modulates protein kinases C (PKC) functions by activating PKCδ and inhibiting PKCa. This study assessed the antiproliferative effects of PEP005 alone and in combination with several other anticancer agents in a panel of 10 human cancer cell lines characterised for expression of several PKC isoforms. PEP005 displayed antiproliferative effects at clinically relevant concentrations with a unique cytotoxicity profile that differs from that of most other investigated cytotoxic agents, including staurosporine. In a subset of colon cancer cells, the IC<sub>50</sub>
 of PEP005 ranged from 0.01 - 140 μM. The antiproliferative effects of PEP005 were shown to be concentration- and time-dependent. In Colo205 cells, apoptosis induction was observed at concentrations ranging from 0.03 to 3 μM. Exposure to PEP005 also induced accumulation of cells in the G I phase of the cell cycle. In addition, PEP005 increased the phosphorylation of PKCδ and p38. In Colo205 cells, combinations of PEP005 with several cytotoxic agents including oxaliplatin, SN38, 5FU, gemcitabine, doxorubicin, vinorelbine, and docetaxel yielded sequence-dependent antiproliferative effects. Cell cycle blockage induced by PEP005 in late Gl lasted for up to 24 h and therefore a 24h lag-time between PEP005 and subsequent exposure to cytotoxics was required to optimise PEP005 combinations with several anticancer agents. These data support further evaluation of PEP005 as an anticancer agent and may help to optimise clinical trials with PEP005-based combinations in patients with solid tumours.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>France</li>
</country>
<region><li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
</settlement>
</list>
<tree><country name="France"><region name="Île-de-France"><name sortKey="Benhadji, K A" sort="Benhadji, K A" uniqKey="Benhadji K" first="K. A." last="Benhadji">K. A. Benhadji</name>
</region>
<name sortKey="Benhadji, K A" sort="Benhadji, K A" uniqKey="Benhadji K" first="K. A." last="Benhadji">K. A. Benhadji</name>
<name sortKey="Calvo, F" sort="Calvo, F" uniqKey="Calvo F" first="F." last="Calvo">F. Calvo</name>
<name sortKey="Cvitkovic, E" sort="Cvitkovic, E" uniqKey="Cvitkovic E" first="E." last="Cvitkovic">E. Cvitkovic</name>
<name sortKey="Faivre, S" sort="Faivre, S" uniqKey="Faivre S" first="S." last="Faivre">S. Faivre</name>
<name sortKey="Ghoul, A" sort="Ghoul, A" uniqKey="Ghoul A" first="A." last="Ghoul">A. Ghoul</name>
<name sortKey="Ghoul, A" sort="Ghoul, A" uniqKey="Ghoul A" first="A." last="Ghoul">A. Ghoul</name>
<name sortKey="Hammel, P" sort="Hammel, P" uniqKey="Hammel P" first="P." last="Hammel">P. Hammel</name>
<name sortKey="Le Tourneau, C" sort="Le Tourneau, C" uniqKey="Le Tourneau C" first="C." last="Le Tourneau">C. Le Tourneau</name>
<name sortKey="Lokiec, F" sort="Lokiec, F" uniqKey="Lokiec F" first="F." last="Lokiec">F. Lokiec</name>
<name sortKey="Raymond, E" sort="Raymond, E" uniqKey="Raymond E" first="E." last="Raymond">E. Raymond</name>
<name sortKey="Serova, M" sort="Serova, M" uniqKey="Serova M" first="M." last="Serova">M. Serova</name>
</country>
<country name="Australie"><noRegion><name sortKey="Ogbourne, S M" sort="Ogbourne, S M" uniqKey="Ogbourne S" first="S. M." last="Ogbourne">S. M. Ogbourne</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008E73 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008E73 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:09-0049469
   |texte=   Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

Serveur d'exploration sur les relations entre la France et l'Australie

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.